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FK 506 has established itself as a promising immuno-
suppressive drug in organ transplantation and in the 
treatment of autoimmune disease. Therapeutic monitoring 
of plasma concentrations of FK 506 is essential to ensure 
appropriate dosage for adequate immunosuppression and 
to minimize potentia! side effects. Routine monitoring of 
FK S06 plasma concentration is performed with an en· 
zyme·linked immunoassay (ELISA) previously developed 
by Tamura et all and modified by Cadoff et al.2 Plasma FK 
506 levels also have been measured with an in vitro 
bioassay.3 This assay is based on the inhibition of the 
ailoantigen driven proliferation of cloned alloreactive T 
cells. These activated lymphocytes show a narrow sensi· 
tivity range to FK S06 and the IC50 is 0.07 to 0.12 nmollL. 
In liver allograft recipients. the FK 506 levels as deter· 
mined by bioassay are consistently lower than those mea-
sured by ELISA (Fig 1). These results suggest that the 
plasma may contain biologically less active FK S06 metab-
olites, which can be detected by ELISA. 
FK 506 METABOLISM 
The liver appears to be the primary site of FK S06 
metabolism. 4 Venkataramanan et a15 have isolated several 
FK S06 metabolites from human and rat bile samples. 
These in vivo generated metabolites represent largely the 
products of demethylation and hydroxylation of FK 506. A 
total of four FK 506 metabolite fractions have been iso-
lated by high performance liquid chromatography (HPLC) 
of rat bile and three fractions were tested for their immu· 
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FIg 2. Effect of different concentrations of FK 506 and metabo-
lites Met ,. Met 2. and Met 3 on donor·specific PL T activity of 
alloreactive T·cell clone 0829. The PL T response of 0829 was 
53.324 :: 3.219. 
nosuppressive activity in an in vitro bioassay with cloned 
alloreactive T cells. Only one of the three fractions showed 
significant inhibition of the PL T activity of an alloreactive 
clone. but at a lOO-fold higher concentration than that of 
the parent drug (Fig 2). Christians et alb identified nine 
metabolites of FK 506 when FK 506 was incubated with 
human liver microsomes. Only two out of nine metabolites 
exhibited significant immunosuppressive activity in vitro. 
but the IC50 values were only 10% or less of the IC50 of 
FK 506. These investigators have developed a specific 
HPLClultraviolet (UV) assay for quantification of FK 506 
and its metabolites in blood. bile. urine. and microsomal 
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fig 3. CorrelatiOn between ELISA and bioassay. FK 506 plasma 
levels (ng/mL) in (A) stable liver transplant recipients (classes I + 
II) and (B) liver transplant recipients with prolonged hepatic 
dysfunction (classes III + IV). 
preparations. 7 The in vivo and in vitro models provide 
opponunities to enhance our understanding of the meta-
bolic pathways of FK 506 and what conditions exen major 
inftuences on FK 506 metabolism and ultimately. the 
clinical efficacy of FK 506. 
CONDITIONS THAT AFFECT FK 506 METABOLISM 
Close pharmacologic monitoring of FK 506 is essential to 
the optimal management of the immunosuppressed pa-
tient. Abu-Elmagd et al8 have recently demonstrated that 
the liver represents a dominant influence on FK 506 
pharmacokinetics. In liver transplant patients. prolonged 
hepatic dysfunction postsurgery causes a rapid and per-
sistent rise in plasma levels of FK 506 as measured by 
ELISA even after dose reduction. FK S06 plasma levels 
correlate directly with serum bilirubin levels. suggesting 
that liver dysfunction interferes with FK S06 metabolism. 8 
As illustrated in Fig I. in liver transplant patients the FK 
506 levels as measured by the bioassay are consistently 
lower than FK 506 levels measured by ELISA. A compar-
ative analysis with five patients categorized as class f~ has 
shown a good correlation (r = .74) between both levels and 
the bioassay values are about two-thirds of the ELISA 
values (Fig 3. left panel). In contrast. in a group of patients 
with hepatic dysfunction (classes 1II and IV. see refS) we 
were unable to demonstrate a significant correlation (r = 
.13) between plasma FK 506 levels measured by both 
assays (Fig 3. right panell. Most plasma with high ELISA 
values showed much lower bioassay values. These obser· 
vations suggest that biologically inactive FK 506 metabo-
lites may accumulate in the plasma in liver transplant 
palients with severe hepatic dysfunction. SlUdies are in 
progress to funher analyze the FK 506 metabolism pat-
terns by HPLC analysisK~ 
Coadministration of other drugs may also affect FK 506 
metabolism by enhancing or inhibiting the cytochrome 
P-450 system. Administration of steroids to patients on FK 
506 increases FK 506 ELISA levels without a proponional 
increase in FK 506 bioassay concentrations. J This may be 
related to the inhibitory effect of steroids on the biliary 
excretion of FK 506 metabolites. 4 Similar observations 
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have been made with cyclosporine (Cy A)-treated patients 
in whom a steroid bolus caused an increase in blood Cy A 
levels measured by radioimmunoassay, and Cy A levels 
determined by HPLC were unaffected. 10 
Consideration must also be given to other drugs that are 
known to inhibit hepatic drug metabolism. A prime exam-
ple is the administration of erythromycin. which is associ-
ated with significant increases in FK S06 levels measured 
by EUSA and bioassay. Even after the doses of FK 506 
had been lowered. the trough plasma levels of FK 506 
remained elevated. We have also observed that ketocona· 
zoic administration may also be associated with increased 
FK 506 plasma levels. 5 Funher studies are necessary to 
evaluate the effects of various drugs on FK 506 metabo-
lism. A better understanding of drug interactions will 
improve the management of allograft recipients on FK 506 
allowing prompt dose adjustments when required. Clinical 
experience has shown that therapeutic FK S06levels of 0.8 
to 2 nglmL are required to control allograft rejection. ~ 
Although rejection is indicated by clinical parameters and 
laboratory measurements of allograft fUnction. the biopsy 
histology generally provided a definitive diagnosis. Al-
lograft biopsies with histologic rejection show infiltration 
by lymphocytes that can now be readily propagated with 
relatively simple culture techniques. II 
PROPAGATION OF LYMPHOCYTES FROM 
TRANSPLANT BIOPSIES- ASSOCIATION WITH 
FK 506 PLASMA LEVELS 
The in vitro culturing of lymphocytes from transplant 
biopsies is based on the concept that the allograft is 
infiltrated by activated T cells that proliferate in the 
presence of interleukin-2 CIL-2). In hean transplant pa-
tients on eyA immunosuppression. lymphocyte growth 
correlates well with the histologic rejection grade of the 
endomyocardial biopsy. 12 Biopsies with greater cellular 
infiltrates yield more lymphocyte cultures. Similar obser-
vations have been made with liver l3 and kidney transplant 
patients. 14.1$ A similar relationship between biopsy growth 
and histologic grade of rejectlon in cardiac recipients on 
FK 50616 has been established. Moreover. the frequency 
of biopsy growth was lower 10 FK 506-treated patients 
than that of patients on CyA-based immunosuppressive 
therapy. These results are consIstent with the previously 
reponed clinical experience of a lower incidence of cellular 
rejection in hean transplant recipients receiving FK 506 
therapy.17 A significant correlation was also observed 
between a positive biopsy growth assay and histologic 
rejection in FK 506-treated liver transplant recipients. 1M A 
significant number of histologIcally negative biopSies Yield 
lymphocyte cultures. Studies on heart transplant patients 
have demonstrated that such growth correlates with a 
higher risk of subsequent rejection. 12 Since biopsy growth 
is a sensitive indicator of rejection. we have analyzed its 
relationship to plasma FK 506 levels in Iiver ls and hean 
transplant patients. It> The results. summarized in Table I. 
IN VITRO ASSESSMENT OF FK 506 
Tible 1. Correlation Betwwn FK 506 PI...". LeYels Ind Biopsy 
Growth of Uver Ina Helrt Tran..,..nt Recipients 
FK 506 Plasma L.ewIs (nmolIL.) 
FK 506 
BiocIsy GrowIh 
T rl/lllllant 
Rec:iIlIents Assay PosiIiYe NegalJYe 
Liver ELISA 1.48 ::: 1.45 4.06 = 5.8 
Bioassay 0.30::: 0.36 0.90::: 0.63 
Heart ELISA 1.27-:: 0.13 2.50 = 0.90 
demonstrate that biopsy growth correlates with signifi-
cantly lower FK 506 levels measured by ELISA. and in the 
liver transplant patients by bioassay as well. They are 
concordant with the clinically derived conclusions about 
therapeutic trough levels of plasma FK 506 in the 0.8 to :2 
nglmL range. ~ 
IMMUNOSUPPRESSIVE DRUG SENSITIVITY 
OF LYMPHOCYTES PROPAGATED FROM 
ALLOGRAFT BIOPSIES 
Transplant biopsy cultures also provide opportunities to 
study lymphocyte sensitivity to immunosuppressive 
drugs. Up to 1000foid differences have been observed in 
the sensitivity of heart biopsy cultured lymphocytes and 
alloreactive T-cell clones from different individuals to 
eyA. I '! In contrast. lymphocytes from different individuals 
exhibit a narrow sensitivity range (up to 10-fold) to FK 
506. Transplant biopsy cultured lymphocytes are also 
useful to evaluate the immunosuppressive activity of drug 
metabolites. 19 
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